Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maplirpacept (PF-07901801) plus tafasitamab and lenalidomide in relapsed/refractory DLBCL not eligible for stem cell transplantation
jRCT2031230151Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of maplirpacept in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Pfizer. Primary endpoints: Dose limiting toxicity rate (Phase 1b) and Objective response rate (Phase 2). Started Aug 2023; status: completed.
02
Drugs
maplirpacept
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2031230151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230151.